While the rapid development of COVID-19 vaccines helped to wind down the pandemic, it also brought to light the many challenges involved in ramping up the production of injectables that must be made in sterile, aseptic environments. Several companies struggled to compress what’s normally a year-long process into a matter of months.
Pitfalls can be avoided, however, by improving planning processes and adopting new technologies to streamline manufacturing. As manufacturers expand beyond small molecules and first-generation biologics into more complex molecules such as gene therapies and mRNA vaccines, they’ll need to embrace these new tools.
- How virtual reality, robotics and other advanced technologies can improve the efficiency and safety of the manufacturing process
- The latest in in isolator-based technologies designed to protect against contamination
- Learnings from the COVID-19 vaccine ramp-up that can be applied to the future production of sterile injectables